Liraglutide

5mg Vial

10mg Vial

2 September 2026Updated 2 September 2026

Liraglutide

Overview Research0 Mechanism Protocols Safety

Discussions

This is Premium content Premium

Create a free account, then upgrade to Premium or Lifetime to unlock the full research article, mechanism of action, results timeline, dosing protocol, and dose calculator for Liraglutide.

Create free account Member login

Full range of benefits for Liraglutide

Improves glycaemic control, lowering HbA1c

Promotes weight loss by reducing appetite and increasing satiety

Slows gastric emptying, reducing postprandial glucose spikes

Stimulates glucose‑dependent insulin secretion, lowering hypoglycaemia risk vs secretagogues

May reduce major adverse cardiovascular events in high‑risk T2D patients (LEADER trial)

Can modestly lower systolic blood pressure

May reduce hepatic fat and improve NAFLD markers in some studies

Improves markers of beta‑cell function and insulin sensitivity

Favourably alters some lipid parameters (e.g., triglycerides)

This peptide's combination-safety and interaction data below always stays visible, regardless of membership.

Warning

Important information. The data compiled from scientific literature is provided for educational purposes. Dosage ranges reflect what is reported in studies and do not constitute a recommendation, prescription, or usage guidance. Health decisions should always be made with a qualified professional.

Peptide Interactions

// 15 known interactions

Synergistic(4)Compatible(3)Monitor(4)Avoid(4)

Use with professional oversight

Sulfonylureas (e.g., gliclazide, glimepiride)

Increased risk of hypoglycaemia when combined with liraglutide; consider dose reduction and monitor blood glucose closely.

Prandial/rapid‑acting insulin

Concurrent use increases hypoglycaemia risk and usually requires careful glucose monitoring and downward titration of meal‑time insulin doses.

Warfarin and other vitamin K antagonists

Changes in oral intake, weight and gastrointestinal absorption with liraglutide may alter INR; monitor anticoagulation parameters after initiation or dose changes.

Renally active or volume‑depleting agents (e.g., loop/thiazide diuretics)

Liraglutide can cause gastrointestinal fluid losses and occasional renal adverse events, so monitor renal function and volume status when co‑prescribing.

All interaction categories

Synergistic (4)

Metformin: Complementary mechanism improving insulin sensitivity and hepatic glucose output that enhances glycaemic control and weight outcomes when added to liraglutide.
SGLT2 inhibitors (e.g., empagliflozin): Provides additive glucose lowering, weight reduction and cardiovascular/renal benefits that are complementary to GLP-1 receptor agonist effects.
Basal insulin (e.g., insulin glargine, degludec): Combining basal insulin with liraglutide improves fasting and overall glycaemic control and may allow lower insulin doses with less weight gain.
Pramlintide (amylin analogue): Targets postprandial glucose and appetite via distinct but complementary pathways, producing additive effects on post‑meal glycaemia and weight loss.

Compatible (3)

Statins (e.g., atorvastatin): No pharmacodynamic or absorption interaction expected; safe to co-administer for cardiovascular risk reduction in patients on liraglutide.
ACE inhibitors (e.g., ramipril): Antihypertensive therapy with ACE inhibitors is generally neutral with liraglutide and commonly co-prescribed without dose adjustment.
Combined oral contraceptives: No clinically relevant interaction with liraglutide; hormonal contraceptive efficacy is not known to be affected.

Monitor (4)

Sulfonylureas (e.g., gliclazide, glimepiride): Increased risk of hypoglycaemia when combined with liraglutide; consider dose reduction and monitor blood glucose closely.
Prandial/rapid‑acting insulin: Concurrent use increases hypoglycaemia risk and usually requires careful glucose monitoring and downward titration of meal‑time insulin doses.
Warfarin and other vitamin K antagonists: Changes in oral intake, weight and gastrointestinal absorption with liraglutide may alter INR; monitor anticoagulation parameters after initiation or dose changes.
Renally active or volume‑depleting agents (e.g., loop/thiazide diuretics): Liraglutide can cause gastrointestinal fluid losses and occasional renal adverse events, so monitor renal function and volume status when co‑prescribing.

Avoid (4)

DPP‑4 inhibitors (e.g., sitagliptin): Overlapping incretin pathway activity offers little additional benefit and may increase adverse effects without clear efficacy gain, so combine cautiously.
Opioids: Both opioids and GLP‑1 receptor agonists slow gastric emptying and may exacerbate gastrointestinal adverse effects or impair oral drug absorption.
Beta‑blockers: Beta‑blockers can blunt adrenergic hypoglycaemia symptoms, complicating detection of liraglutide‑associated hypoglycaemia in insulin‑treated patients.
Systemic corticosteroids: Corticosteroids antagonise glycaemic control and may necessitate adjustment of liraglutide or concomitant antihyperglycaemic therapy due to worsened hyperglycaemia.